Abstract
The amination of 2-nitroquinizarine using hydroxylamine gives 2-amino-3-nitroquinizarine, which, upon reduction, gives previously unreported 2,3-diaminoquinizarine, a key intermediate in the synthesis of heterocyclic analogs of 5,12-naphthacenequinone, namely, 4,11-dihydroxyanthra[2,3-d]imidazole-5,10-dione (imidazoloquinizarine), 4,11-dihydroxyanthra[2,3-d][1,2,3]triazole-5,10-dione (triazoloquinizarine), and 5,12-dihydroxynaphtho[2,3-g]quinoxaline-6,11-dione (pyrazinoquinizarine).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
R. C. Pandey, M. W. Toussaint, J. C. McGuire, and M. C. Thomas, J. Antibiot., 42, 1567 (1989).
Y. Yamashita, Y. Sattoh, K. Ando, K. Takahashi, H. Ouno, and H. Nakano, J. Antibiot. 43, 1344 (1990).
G. F. Gauze and Yu. V. Dudnik, Antitumor Antibiotics [in Russian], Meditsina, Moscow (1987), p. 44.
M. D. Mashkovskii, Drugs [in Russian], Vol. 2, Izd. Novaya Volna, Moscow (2000), p. 298.
D. Powell, J. Skotnicki, and J. Upeslacis, Ann. Rep. Med. Chem., 32, 165 (1997).
G. W. Rewcastle, B. D. Palmer, A. J. Bridger, H. D. H. Showalter, L. Sun, J. Nelson, A. McMichel, A. J. Kraker, D. W. Fry, and W. A. Denny, J. Med. Chem., 39, 918 (1996).
K. Maeda, T. Osato, and H. Umezava, J. Antibiot., 6, 182 (1953).
S. H. Krawczyk and N. Bischofberger, Ann. Rep. Med. Chem., 32, 143 (1997).
R. Zhou, K. R. Ayrey, J. C. Drach, and L. B. Townsend, J. Med. Chem., 39, 3477 (1996).
S. Saluja, R. Zhou, J. C. Drach, and L. B. Townsend, J. Med. Chem., 39, 881 (1996).
C. Fernandez, U. Martin-Escudero, and M. Izguierdo, Rev. Clinica Espanola, 135, 539 (1974).
C. Fernandez. U. Martin-Escudero, and M. Izguierdo, Rev. Clinica Espanola, 141, 51 (1976).
M. F. Brana, J. M. Castellano, G. Keilhauer, A. Machuca, Y. Martin, C. Redondo, E. Schlick, and N. Walker, Anti-Cancer Drug Design, 9, 527 (1994).
B. C. Baguley, Anti-Cancer Drug Design, 6, 8 (1991).
W. A. Denny, Anti-Cancer Drug Design, 4, 249 (1989).
Z. Mezarska, E. Augustin, and J. Dzeigielewski, Anti-Cancer Drug Design, 11, 73 (1996).
B. J. Foster, K. Clagett-Carr, and D. D. Shoemaker, Investigational New Drugs, 3, 403 (1985).
C. N. Nyujen, F. Fan, and J. F. Rion, Anti-Cancer Drug Design, 10, 277 (1995).
L. W. Deady, A. J. Kaye, G. J. Finlay, B. C. Baguley, and W. A. Denny, J. Med. Chem., 40, 2040 (1997).
M. V. Gorelik, Chemistry of Anthraquinones and Their Derivatives [in Russian], Khimiya, Moscow (1983), p. 154.
D. Jeziorek, D. Dyl, A. Liwo, W. Woznicki, A. Tempezyk, and E. Borowski, Anti-Cancer Drug Design, 8, 223 (1993).
G. Gassinelli, F. Di Matteo, and S. Fomerza, J. Antibiot., 33, 1468 (1980).
A. C. Sartolrelli, ACS Symposium Series, Cancer Chemotherapy (Washington, DC), 30, 41 (1976).
A. E. Shchekotikhin, E. P. Baberkina, V. N. Buyanov, K. F. Turchin, and N. N. Suvorov, Khim. Geterotsikl. Soedin., 1030 (2001).
A. E. Shchekotikhin, D. A. Silaev, E. P. Baberkina, I. G. Makarov, V. N. Buyanov, and N. N. Suvorov, Khim. Geterotsikl. Soedin., 623 (2002).
J. Meisenheimer and E. Patzig, Ber., 39, 2533 (1906).
M. C. Marschalk, Bull. Soc. Chim. France, 5, 629 (1937).
Bayer & Co., German Patent 272,299; Frdl., 11, 590 (1915).
J. B. Wright, Chem. Rev., 48, 401 (1951).
M. V. Gorelik, Chemistry of Anthraquinones and Their Derivatives [in Russian], Khimiya, Moscow (1983), p. 85.
V. Ya. Fain, Electronic Absorption Spectra and the Structure of Anthraquinones. Disubstituted 9,10-Anthraquinones [in Russian], Vol. 2, Sputnik+ (2003), p. 83.
Author information
Authors and Affiliations
Additional information
__________
Translated from Khimiya Geterotsiklicheskikh Soedinenii, No. 7, pp. 1081–1088, July, 2005.
Rights and permissions
About this article
Cite this article
Shchekotikhin, A.E., Makarov, I.G., Buyanov, V.N. et al. Heterocyclic Analogs of 5,12-Naphthacenequinone. 1. Synthesis of Heterocyclic Analogs Starting from 2,3-Diaminoquinizarine. Chem Heterocycl Compd 41, 914–920 (2005). https://doi.org/10.1007/s10593-005-0248-7
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10593-005-0248-7